Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While sales of key drugs Vivitrol and Aristada continue to grow rapidly, Alkermes' overall revenue growth came in much weaker than expected. As a result, management dialed back its revenue growth expectations for the full year. However, containment efforts helped the company to beat expectations on the bottom-line.
Data source: Alkermes. GAAP = generally accepted accounting principles.
Image source: Getty Images.
Source: Fool.com
Alkermes plc Aktie
24,00 €
-4,76 %
Des weiteren hat Alkermes plc derzeit 17 Buy-Einschätzungen und 2 Sell-Einschätzungen durch unsere Community zu Buche stehen.
Das Kursziel von 35 € für Alkermes plc bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 24.0 €.
